UK markets open in 7 hours 35 minutes

BMY Jan 2025 45.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.1000-0.1000 (-2.38%)
As of 12:50PM EDT. Market open.
Full screen
Previous close4.2000
Open4.2900
Bid4.0500
Ask4.1500
Strike45.00
Expiry date2025-01-17
Day's range4.0700 - 4.3200
Contract rangeN/A
Volume685
Open interest7.81k
  • GlobeNewswire

    Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

    Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer

  • Insider Monkey

    Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript

    Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $-4.4, expectations were $-4.55. Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers […]

  • Zacks

    Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

    Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.